{"entity":{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","aka":[],"tldr":"Academic hospitals can already make CAR-T cells for a fraction of the commercial price. A public network would scale that so more patients can be treated for less.","summary":"Point-of-care manufacturing of CAR-T and other autologous cell therapies in a network of accredited academic hospitals, using shared vectors, harmonised processes and closed automated systems, with regulatory approval as a hospital-exemption or public product rather than a commercial licence. Spain's ARI-0001 (Hospital Clínic Barcelona) was approved by the national agency as a hospital-made CD19 CAR-T at a reported cost far below commercial products; India and Brazil have followed with domestic academic products. A network would share process, quality and pharmacovigilance and could supply public health systems at cost.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)","url":"https://doi.org/10.1038/d41573-022-00030-4"}],"tags":[],"related":["idea-fund-pay-for-cure-annuities","idea-fund-hospital-exemption-registry"],"cancers":["dlbcl","all-leukemia","multiple-myeloma"],"sections":[],"technologies":["car-t","allogeneic-cell-therapy"],"targets":["cd19","bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cartitude-4","karmma-3","nct06413498","nct06464991","zuma-7"],"people":[],"bottlenecks":["b-incentive-misalignment","b-manufacturing-cell-therapy","b-drug-pricing"],"keyPapers":["paper-upadhaya-nat-rev-drug-discov","paper-cd19-all-leukemia-j-clin-invest-2016","paper-cd19-all-leukemia-j-clin-oncol-2014","paper-cd19-all-leukemia-blood-2015"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A ten-hospital public CAR-T network delivers CD19 and BCMA CAR-T with efficacy and safety non-inferior to commercial products in registry comparison, at a fully-loaded cost per treated patient under a third of commercial list prices, and doubles the number of eligible patients treated in its regions within four years.","rationale":"ARI-0001 and academic products elsewhere demonstrate feasibility and regulatory acceptance; academic manufacturing removes the margin and much of the logistics cost. Capacity, not biology, currently rations CAR-T in most of the world.","test":"Fund a five-centre pilot with a shared vector and process, register a prospective comparative registry against commercial products, and report outcomes and cost at three years.","maturity":"early-clinical","actor":"clinic","cost":"large","horizonYears":4},"route":"/ideas/idea-fund-public-car-t-manufacturing/","neighbours":{"idea":[{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/"},{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/"},{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/"},{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","route":"/ideas/idea-fund-shared-personalised-therapy-gmp/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"trial":[{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/"},{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/"},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/"},{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-cd19-all-leukemia-j-clin-invest-2016","kind":"paper","name":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","route":"/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/"},{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/"},{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/"},{"id":"paper-cd19-all-leukemia-j-clin-oncol-2014","kind":"paper","name":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}